Regis Healthcare Limited (ASX:REG): FY26 Earnings, Aged Care Expansion and Operating Costs

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Regis Healthcare Limited (ASX:REG): FY26 Earnings, Aged Care Expansion and Operating Costs

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Regis Healthcare (ASX:REG) reported FY26 service revenue of AUD 1,350.6 million, up 16.3%.
Underlying FY26 EBITDA rose 9.7% to AUD 138.0 million; statutory NPAT reached AUD 55.7 million.
Mature-home occupancy averaged 96.0%, while FY26 net operating cash flow totalled AUD 336.3 million.
The development pipeline comprised approximately 1,300 beds across nine sites at the FY26 update.

Regis Healthcare Limited (ASX:REG) operates Australian residential aged care homes alongside home care, respite, day therapy and retirement living services. On 22 October 2026, the shares were quoted at AUD 4.72, up 0.86% for the session. The company’s latest full-year disclosures recorded higher service revenue, acquisitions and development expenditure, together with rising workforce costs. Its FY26 report provides the principal basis for assessing the operating position and planned capacity additions.

Company Business

Regis Healthcare Limited (ASX:REG) delivers nursing, personal care and accommodation through its residential network. Services include dementia support, palliative care and temporary respite, while home care and allied health activities serve people outside residential facilities. The group also operates retirement villages. Its Australian footprint spans multiple states and the Northern Territory, exposing the business to changes in aged care funding, staffing requirements and local accommodation demand.

The operating model combines resident payments, accommodation arrangements and government-funded care. Occupancy, room pricing, workforce deployment and care minutes therefore affect financial outcomes. The company’s FY26 operational report recorded 2.85 million occupied bed days, compared with 2.63 million in FY25, and mature-home average occupancy of 96.0%, against 95.6% a year earlier.

Recent Development

In August 2026, Regis Healthcare Limited (ASX:REG) reported that it had completed the acquisitions of four Rockpool homes with 600 beds in southeast Queensland and two OC Health facilities with 230 beds in Victoria during FY26. It also sold its Ayr and Home Hill facilities in March 2026, recognising a one-off AUD 25.4 million pretax profit. These transactions changed its geographic and asset mix during the reporting year.

Construction of the 123-bed Toowong home in Brisbane was nearing completion at the FY26 results announcement, with an opening planned for summer 2026–27. Work at Carlingford was also under way. Regis disclosed a development pipeline of approximately 1,300 beds over nine sites. These are company plans rather than completed additions, and their timing remains subject to construction and commissioning progress.

Financial Performance and Sector Context

Regis Healthcare Limited (ASX:REG) recorded FY26 service revenue of AUD 1,350.6 million, compared with AUD 1,161.3 million in FY25, an increase of 16.3%. The company cited higher Australian National Aged Care Classification pricing, the hotelling supplement, acquisitions and occupancy. Underlying EBITDA was AUD 138.0 million versus AUD 125.8 million, although the underlying EBITDA margin declined from 10.8% to 10.2%.

Statutory net profit after tax was AUD 55.7 million, compared with AUD 49.0 million in FY25. Underlying NPAT was AUD 55.6 million versus AUD 53.4 million. Net operating cash flow reached AUD 336.3 million, including AUD 250.5 million of net refundable accommodation deposit inflows. Net cash stood at AUD 173.8 million on 30 June 2026, down from AUD 192.5 million a year earlier.

Staff expenditure increased to AUD 1,055.1 million from AUD 889.0 million, reflecting wage changes, workforce expansion and mandated care requirements. Staff expenses represented 78.1% of service revenue, against 76.6% in FY25. Capital expenditure rose to AUD 143.1 million from AUD 88.1 million, covering land, developments and existing-home improvements. The new Aged Care Act commenced in November 2025 and changed certain funding and accommodation arrangements.

Risks to Consider

Regis Healthcare Limited (ASX:REG) faces staff-cost inflation, care delivery obligations and funding indexation that may not match expenses. Occupancy changes and accommodation deposit inflows can affect cash availability. Development projects carry building, commissioning and occupancy-ramp risks; acquisitions require integration. Refundable accommodation deposits are also associated with repayment liabilities, making the composition of operating cash flow important when examining liquidity.

What to Watch Next

Upcoming disclosures may clarify progress at Toowong and Carlingford, the contribution from acquired facilities and trends in mature-home occupancy. Regis had repriced approximately 70% of rooms in July and August 2026, raising average advertised prices by 10%; subsequent disclosures may indicate how pricing changes translate into realised deposits and income. Labour costs, care funding, capital spending and available cash will remain measurable operational indicators.

Key Insights

Regis Healthcare Limited (ASX:REG) ended FY26 with higher revenue and earnings, increased occupied bed days and material accommodation deposit inflows. Its EBITDA margin nevertheless narrowed as costs rose. The balance between existing-home performance, financing needs, regulatory settings and delivery of new facilities will determine which operating metrics deserve attention in subsequent company reports.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.